SRNE Sorrento Therapeutics Inc

Price (delayed)

$6.65

Market cap

$1.91B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.93

Enterprise value

$2.02B

Sector: Healthcare
Industry: Biotechnology

Highlights

SRNE's equity has soared by 129% YoY and by 40% QoQ
The company's gross profit has surged by 73% YoY and by 19% QoQ

Key stats

What are the main financial stats of SRNE
Market
Shares outstanding
286.65M
Market cap
$1.91B
Enterprise value
$2.02B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.05
Price to sales (P/S)
40.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
43.41
Earnings
Revenue
$46.52M
EBIT
-$216.98M
EBITDA
-$202.49M
Free cash flow
-$177.54M
Per share
EPS
-$0.93
Free cash flow per share
-$0.63
Book value per share
$0.83
Revenue per share
$0.17
TBVPS
$1.77
Balance sheet
Total assets
$613.62M
Total liabilities
$382.73M
Debt
$154.76M
Equity
$231.44M
Working capital
$169.66M
Liquidity
Debt to equity
0.67
Current ratio
2.77
Quick ratio
2.63
Net debt/EBITDA
-0.56
Margins
EBITDA margin
-435.3%
Gross margin
76.6%
Net margin
-496%
Operating margin
-615.3%
Efficiency
Return on assets
-40.4%
Return on equity
-124.8%
Return on invested capital
-44.8%
Return on capital employed
-41.9%
Return on sales
-466.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SRNE stock price

How has the Sorrento Therapeutics stock price performed over time
Intraday
0.45%
1 week
-1.92%
1 month
-11.21%
1 year
-1.63%
YTD
-2.64%
QTD
-19.59%

Financial performance

How have Sorrento Therapeutics's revenue and profit performed over time
Revenue
$46.52M
Gross profit
$35.63M
Operating income
-$286.26M
Net income
-$230.76M
Gross margin
76.6%
Net margin
-496%
The company's gross profit has surged by 73% YoY and by 19% QoQ
Sorrento Therapeutics's operating income has shrunk by 60% YoY and by 17% QoQ
The revenue has increased by 41% YoY and by 16% from the previous quarter
Sorrento Therapeutics's net margin has increased by 34% YoY and by 34% QoQ

Growth

What is Sorrento Therapeutics's growth rate over time

Valuation

What is Sorrento Therapeutics stock price valuation
P/E
N/A
P/B
8.05
P/S
40.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
43.41
The EPS rose by 45% YoY and by 28% QoQ
SRNE's equity has soared by 129% YoY and by 40% QoQ
SRNE's price to book (P/B) is 71% more than its 5-year quarterly average of 4.7 but 26% less than its last 4 quarters average of 10.9
SRNE's price to sales (P/S) is 55% higher than its 5-year quarterly average of 25.9 but 18% lower than its last 4 quarters average of 48.7
The revenue has increased by 41% YoY and by 16% from the previous quarter

Efficiency

How efficient is Sorrento Therapeutics business performance
The ROE has soared by 61% YoY and by 36% QoQ
The ROS rose by 33% QoQ and by 29% YoY
The return on assets has grown by 25% since the previous quarter and by 9% year-on-year
The return on invested capital has increased by 22% since the previous quarter but it has declined by 15% year-on-year

Dividends

What is SRNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRNE.

Financial health

How did Sorrento Therapeutics financials performed over time
Sorrento Therapeutics's total assets is 60% higher than its total liabilities
The total liabilities has declined by 21% year-on-year and by 3.1% since the previous quarter
Sorrento Therapeutics's total assets has increased by 15% QoQ and by 14% YoY
Sorrento Therapeutics's debt is 33% lower than its equity
SRNE's equity has soared by 129% YoY and by 40% QoQ
Sorrento Therapeutics's debt to equity has shrunk by 73% YoY and by 35% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.